Investigation of the BRAF V600E mutation by pyrosequencing in lymphoproliferative disorders

American Journal of Clinical Pathology

Volumn 138, Issue 6, 2012, Pages 877-883

  Laurini, Javier A ^a   Aoun, Patricia ^a   Iqbal, Javeed ^a   Chan, Wing ^a   Greiner, Timothy C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

BRAF mutations; Hairy cell leukemia; Lymphoma; PTLD; Pyrosequencing

Indexed keywords

B RAF KINASE; DNA;

ARTICLE; DNA EXTRACTION; DNA SEQUENCE; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HAIRY CELL LEUKEMIA; HUMAN; LARGE CELL LYMPHOMA; LARGE GRANULAR LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MARGINAL ZONE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; POLYMERASE CHAIN REACTION; POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PYROSEQUENCING; SENSITIVITY ANALYSIS; T CELL LYMPHOMA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; DNA, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, HAIRY CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84869232543     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP5TWORA0TMXGL     Document Type: Article

References (40)

1. Foucar K, Fallini B, Catovsky D, et al. Hairy cell leukemia. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008:188-190.
2. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004;363:1869-1870.
3. Sherman MJ, Hanson CA, Hoyer JD. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol. 2011;136:390-399.
4. Basso K, Liso A, Tiacci E, et al. Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors. J Exp Med. 2004;199:59-68. (Pubitemid 38076478)
5. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-2315.
6. Tiacci E, Schiavoni G, Forconi F, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192-195.
7. Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119:188-191.
8. Langabeer SE, O'Brien D, Liptrot S, et al. Correlation of the BRAF V600E mutation in hairy cell leukaemia with morphology, cytochemistry and immunophenotype. Int J Lab Hematol. 2012;34:417-421.
9. Boyd EM, Bench AJ, van't Veer MB, et al. High resolution melting analysis for detection of BRAF exon 15 mutations in hairy cell leukaemia and other lymphoid malignancies. Br J Haematol. 2011;155:609-612.
10. Blombery P, Wong SQ, Hewitt CA, et al. Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders. Haematologica. 2012;97:780-783.
11. Ewalt M, Nandula S, Phillips A, et al. Real-time PCR-based analysis of BRAF V600E mutation in low and intermediate grade lymphomas confirms frequent occurrence in hairy cell leukaemia [published online ahead of print December 22, 2011]. Hematol Oncol.
12. Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2011;157:267-269.
13. Lennerz JK, Klaus BM, Marienfeld RB, et al. Pyrosequencing of BRAF V600E in routine samples of hairy cell leukaemia identifies CD5+ variant hairy cell leukaemia that lacks V600E. Br J Haematol. 2011;157:267-269.
14. Langabeer SE, Quinn F, O'Brien D, et al. Incidence of the BRAF V600E mutation in chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Res. 2012;36:483-484.
15. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol. 2010;80:561-567.
16. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev. 2007;17:31-39. (Pubitemid 46109299)
17. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147. (Pubitemid 41653105)
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
19. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res. 2004;10:191-195. (Pubitemid 38114179)
20. Schmid K, Oehl N, Wrba F, et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15:4554-4560.
21. Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol. 2011;29:2046-2051.
22. Puxeddu E, Durante C, Avenia N, et al. Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab. 2008;19:138-145. (Pubitemid 351621952)
23. Ciampi R, YE. Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148:936-941.
24. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919-1923.
25. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
26. Ronaghi M, Karamohamed S, Pettersson B, et al. Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem. 1996;242:84-89. (Pubitemid 26378519)
27. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007;9:464-471. (Pubitemid 47434113)
28. Tan YH, Liu Y, Eu KW, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40:295-298. (Pubitemid 351563933)
29. Richman SD, Chambers P, Seymour MT, et al. Intratumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst). 2011;34:61-66.
30. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931-5937.
31. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res. 2001;11:3-11. (Pubitemid 32117949)
32. Verma S, Greaves WO, Ravandi F, et al. Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012;138:153-156.
33. Arons E, Suntum T, Stetler-Stevenson M, et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687-4695.
34. Gustafsso B, Angelini S, Sander B, et al. Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia. 2005;19:310-312. (Pubitemid 40220605)
35. Davidsson J, Lilljebjorn H, Panagopoulos I, et al. BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias. Leukemia. 2008;22:1619-1621.
36. Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res. 2008;68:6803-6809.
37. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467-472.
38. Lee JW, Yoo NJ, Soung YH, et al. BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer. 2003;89:1958-1960.
39. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
40. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.